Maze Therapeutics, Inc.
Maze Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).
The next scheduled catalyst is Next quarterly earnings (projected) on November 9, 2026, a projected date rather than a confirmed one. There are 2 upcoming events on record.
Cash runway is approximately 31.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.
| Date | Event | Type | Phase |
|---|---|---|---|
| November 9, 2026 est. | Next quarterly earnings (projected) | Earnings | — |
| December 15, 2027 | A Study of MZE782 in Adults With PKU | Trial Milestone | Phase 2 |
Track MAZE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open MAZE in the tracker| Date | Event | Type | Phase |
|---|---|---|---|
| September 15, 2026 | A Phase 2 Study of MZE829 in Adults With APOL1 Kidney Disease | Trial Milestone | Phase 2 |
| August 17, 2026 | 8-K filed: Leadership change, Reg FD disclosure | Corporate | — |
| August 11, 2026 | Quarterly results filed (8-K) | Earnings | — |
| May 22, 2026 | 8-K filed: Leadership change | Corporate | — |
| May 12, 2026 | Quarterly results filed (8-K) | Earnings | — |
| April 22, 2026 | 8-K filed: Other event | Filing | — |
| March 25, 2026 | Quarterly results filed (8-K) | Earnings | — |
| February 4, 2026 | 8-K filed: Material agreement | Corporate | — |
| November 6, 2025 | Quarterly results filed (8-K) | Earnings | — |
| October 6, 2025 | 8-K filed: Leadership change | Corporate | — |
| September 11, 2025 | 8-K filed: Material agreement, Reg FD disclosure | Corporate | — |
| September 2, 2025 | 8-K filed: Leadership change | Corporate | — |
| August 12, 2025 | Quarterly results filed (8-K) | Earnings | — |
| May 14, 2025 | Quarterly results filed (8-K) | Earnings | — |
| December 21, 2022 | A Randomized Phase 1 of of MZE001 in Healthy Volunteers | Trial Milestone | Phase 1 |
Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.